Cardiology

Your Article Summary

See Latest Articles

CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men
Journal of Hypertension, 09/28/09

Donner KM et al. – The CYP2C9*3 allele was associated with lower activity of the renin–angiotensin–aldosterone system in hypertensive men, which may reflect a more efficient sodium reabsorption capacity. CYP2C9*2 and CYP2C9*3 alleles do not influence the antihypertensive effect of losartan in men with essential hypertension and normal kidney function.

Today in Basic Science/Genetics...keeping you current

Receive free subspecialty "5-minute updates" via email

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09

Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis
Arthritis Care and Research , 11/03/09

Benefits and Difficulties in Measuring HDL Subfractions and Human Paraoxonase-1 Activity During Statin Treatment
Cardiovascular Drugs and Therapy, 11/03/09

See All of Basic Science/Genetics

Today in Hypertension...keeping you current

Receive free subspecialty "5-minute updates" via email

Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy
Current Medical Research and Opinion, 11/23/09

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09

Current options for the treatment of resistant hypertension
Expert Review of Cardiovascular Therapy , 11/13/09

See All of Hypertension